Biocept, Inc. (NASDAQ: BIOC)
Biocept is a molecular diagnostics company that has focused on the development and commercialization of liquid biopsies. Their ultimate goal is to improve the detection and treatment of cancer; and today, they’ve made an announcement that may help with doing just that. Today, Biocept announced that it has entered into a clinical collaboration with Sarah Cannon Research Institute. Today, we’ll talk about the collaboration and the company’s goal behind the collaboration, we’ll also talk about how the market reacted to the news and what we can expect to see from Biocept moving forward. So, let’s get right to it.
Biocept Joins Forces With Sarah Cannon Research Group
Sarah Cannon Research Group is the research arm for a global cancer enterprise of Hospital Corporation of America, known simply as Sarah Cannon. The goal behind the collaboration is simple. BIOC hopes to determine the clinical utility of detecting biomarkers present in circulating tumor cells and circulating turm DNA in blood samples of estrogen positive breast cancer patients. In a statement, SVP and senior medical director of Biocept, Veena Singh, MD. had the following to say…
“The goal of our collaboration with Sarah Cannon is to identify biomarkers that can be evaluated through a simple blood draw, without continually performing tissue biopsies on a patient…By using a blood sample to screen these patients, we seek to help more patients qualify for new drug therapies that can more effctively target cancer.”
The statement above was followed by Erika P. Hamilton, MD. and associate Director of the Breast Cancer and Gynecologic Cancer Research Program at SCRI who had the following to say…
“Breast cancer is the most prevalent cancer in women, and more than two-thirds of cases express estrogen receptor (ER). It is encouraging to see targeted therapies for patients with ER+ disease, which included recently approved drugs as well as newer options currently available in clinical trials….Understanding a patient’s ER status at the time of diagnosis or recurrence, and then monitoring throughout the patient’s treatment, is becoming increasingly more important.”
How BIOC Reacted To The News In The Market
BIOC is up today, but not by much. Currently (12:03), the stock is trading at $3.41 per share after a slight gain of 2.10% so far today.
What We Can Expect To See Moving Forward
Moving forward, I’m expecting to see overwhelmingly positive news from Biocept. In my opinion, the company’s innovation in the detection of cancer isn’t simply interesting, it’s profitable. Think about it, one of the biggest reasons that people die from cancer is because it was caught too late. By improving upon the way cancer is diagnosed, Biocept has the ability to improve survival rates in those suffering from the ailment. Throughout the past several months, we have seen more and more proof that Biocept is a strong company; and today’s news just adds icing to the cake. All in all, I’m incredibly excited for what we’re likely to see from the stock moving forward.
What Do You Think?
Where do you think BIOC is headed and why? Let us know in the comments below!